表紙
市場調査レポート

アヘン (オピオイド) 中毒:パイプライン製品の分析

Opium (Opioid) Addiction - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 192749
出版日 ページ情報 英文 91 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
アヘン (オピオイド) 中毒:パイプライン製品の分析 Opium (Opioid) Addiction - Pipeline Review, H1 2016
出版日: 2016年04月13日 ページ情報: 英文 91 Pages
概要

オピオイド中毒は、ある時期、オピオイドを定期的に使用していた後に発症します。アヘン (鎮静剤) の長期使用は、脳内の神経障害を引き起こします。痛みを軽減する神経細胞の変性によって、外部の供給源としてアヘン (鎮静剤) への身体的依存をもたらします。兆候や症状には、強い不安感、高揚感、精神病、抑鬱感、高血圧、食欲減退、身体的興奮、睡眠障害、骨の痛みなどがあります。素因として、年齢、薬物乱用の既往歴、薬物乱用の家族歴、タバコへの依存、精神的ストレスなどが挙げられます。

当レポートでは、アヘン (オピオイド) 中毒に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

アヘン (オピオイド) 中毒の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

アヘン (オピオイド) 中毒:企業で開発中の治療薬

アヘン (オピオイド) 中毒:大学/機関で研究中の治療薬

アヘン (オピオイド) 中毒:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

アヘン (オピオイド) 中毒:企業で開発中の製品

アヘン (オピオイド) 中毒:大学/機関で研究中の製品

アヘン (オピオイド) 中毒の治療薬開発に従事している企業

  • Alkermes Plc
  • Aoxing Pharmaceutical Company, Inc
  • BioDelivery Sciences International, Inc.
  • Camurus AB
  • Foresee Pharmaceuticals, LLC
  • Heron Therapeutics, Inc.
  • Indivior Plc
  • INSYS Therapeutics, Inc.
  • Omeros Corporation
  • Pfizer Inc.
  • Relmada Therapeutics, Inc.
  • Titan Pharmaceuticals, Inc.
  • Zynerba Pharmaceuticals, Inc.

アヘン (オピオイド) 中毒:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

アヘン (オピオイド) 中毒:最近のパイプライン動向

アヘン (オピオイド) 中毒:休止中のプロジェクト

アヘン (オピオイド) 中毒:開発が中止された製品

アヘン (オピオイド) 中毒:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7854IDB

Summary

Global Markets Direct's, 'Opium (Opioid) Addiction - Pipeline Review, H1 2016', provides an overview of the Opium (Opioid) Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction
  • The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects
  • The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Opium (Opioid) Addiction Overview
  • Therapeutics Development
    • Pipeline Products for Opium (Opioid) Addiction - Overview
    • Pipeline Products for Opium (Opioid) Addiction - Comparative Analysis
  • Opium (Opioid) Addiction - Therapeutics under Development by Companies
  • Opium (Opioid) Addiction - Therapeutics under Investigation by Universities/Institutes
  • Opium (Opioid) Addiction - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Opium (Opioid) Addiction - Products under Development by Companies
  • Opium (Opioid) Addiction - Products under Investigation by Universities/Institutes
  • Opium (Opioid) Addiction - Companies Involved in Therapeutics Development
    • Alkermes Plc
    • Aoxing Pharmaceutical Company, Inc
    • BioDelivery Sciences International, Inc.
    • Camurus AB
    • Foresee Pharmaceuticals, LLC
    • Heron Therapeutics, Inc.
    • Indivior Plc
    • INSYS Therapeutics, Inc.
    • Omeros Corporation
    • Pfizer Inc.
    • Relmada Therapeutics, Inc.
    • Titan Pharmaceuticals, Inc.
    • Zynerba Pharmaceuticals, Inc.
  • Opium (Opioid) Addiction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Buprenorphine Hemiadipate Hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buprenorphine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buprenorphine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buprenorphine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buprenorphine hydrochloride depot - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buprenorphine hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buprenorphine hydrochloride long acting - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buprenorphine hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cannabidiol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FP-004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMS-405 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-5006739 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • samidorphan l-malate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TA-CD - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Opium Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Opium (Opioid) Addiction - Recent Pipeline Updates
  • Opium (Opioid) Addiction - Dormant Projects
  • Opium (Opioid) Addiction - Discontinued Products
  • Opium (Opioid) Addiction - Product Development Milestones
    • Featured News & Press Releases
      • Mar 04, 2016: BioDelivery Sciences to provide an update on Buprenorphine Injection at the Cowen And Company 36th Annual Healthcare Conference and the 28th Annual Roth Conference
      • Feb 19, 2016: Titan Pharmaceuticals Announces Notification of FDA Action Date Extension for Probuphine
      • Feb 16, 2016: TSRI Scientists Create Vaccine Against Dangerous Designer Opioids
      • Jan 13, 2016: Segal Institute for Clinical Research Proudly Participates in Phase 3 Efficacy Trial of Long-Acting Treatment Opioid Dependence
      • Jan 12, 2016: Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction
      • Dec 30, 2015: Braeburn Pharmaceuticals and Camurus Enroll First Patient in a Phase 3 Efficacy Trial of Long-Acting Treatment for Opioid Dependence
      • Dec 15, 2015: Braeburn Pharmaceuticals and Camurus announce start of Phase 3 trial of long-acting buprenorphine treatments for opioid dependence
      • Dec 09, 2015: Braeburn Pharmaceuticals and Titan Pharmaceuticals Announce Date of FDA Advisory Committee Review of Probuphine for Opioid Addiction
      • Dec 09, 2015: Relmada Therapeutics Announces Positive Topline Results for Proof-of-Concept Study with BuTab
      • Dec 09, 2015: Relmada Therapeutics Announces Positive Topline Results for Proof-of-Concept Study with BuTab
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Opium (Opioid) Addiction, H1 2016
  • Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H1 2016
  • Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company, Inc, H1 2016
  • Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International, Inc., H1 2016
  • Opium (Opioid) Addiction - Pipeline by Camurus AB, H1 2016
  • Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016
  • Opium (Opioid) Addiction - Pipeline by Heron Therapeutics, Inc., H1 2016
  • Opium (Opioid) Addiction - Pipeline by Indivior Plc, H1 2016
  • Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics, Inc., H1 2016
  • Opium (Opioid) Addiction - Pipeline by Omeros Corporation, H1 2016
  • Opium (Opioid) Addiction - Pipeline by Pfizer Inc., H1 2016
  • Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics, Inc., H1 2016
  • Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals, Inc., H1 2016
  • Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Opium (Opioid) Addiction Therapeutics - Recent Pipeline Updates, H1 2016
  • Opium (Opioid) Addiction - Dormant Projects, H1 2016
  • Opium (Opioid) Addiction - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Opium (Opioid) Addiction, H1 2016
  • Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top